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Abstract
Background:  Chronic  N-Methyl-d-aspartate (NMDA) administration to rats is reported to
increase arachidonic acid signaling and upregulate neuroinflammatory markers in rat brain. These
changes may damage brain cells. In this study, we determined if chronic NMDA administration (25
mg/kg i.p., 21 days) to rats would alter expression of pro- and anti-apoptotic factors in frontal
cortex, compared with vehicle control.
Results: Using real time RT-PCR and Western blotting, chronic NMDA administration was shown
to decrease mRNA and protein levels of anti-apoptotic markers Bcl-2 and BDNF, and of their
transcription factor phospho-CREB in the cortex. Expression of pro-apoptotic Bax, Bad, and 14-3-
3ζ was increased, as well as Fluoro-Jade B (FJB) staining, a marker of neuronal loss.
Conclusion: This alteration in the balance between pro- and anti-apoptotic factors by chronic
NMDA receptor activation in this animal model may contribute to neuronal loss, and further
suggests that the model can be used to examine multiple processes involved in excitotoxicity.
Background
Glutamate is the major excitatory neurotransmitter in ver-
tebrate brain. Glutamate acts on two different classes of
receptors, ionotropic glutamatergic receptors and G-pro-
tein-coupled metabotropic receptors. The ionotropic
receptors are further classified into α-amino-3-hydroxyl-
5-methyl-4-isoxazole-propionate (AMPA), kainate, and
N-methyl-D-aspartate (NMDA) receptors [1]. Binding of
glutamate to NMDA receptors (NMDAR) results in an
influx of extracellular Ca2+ into the cell, which leads to the
activation of many Ca2+-dependent enzymes such as cal-
pain [2], calcineurin [3], inducible nitric oxide synthase
(iNOS) expression [4] and arachidonic acid (AA, 20:4n-6)
selective cytosolic phospholipase A2(cPLA2)[5,6].
NMDAR are present throughout the brain and predomi-
nantly in frontal cortex and hippocampal CA1 region [7].
Activation of NMDAR also induces signaling cascades
involved in learning and memory, synaptic excitability
and plasticity, and neuronal degeneration [8]. Overactiva-
tion of glutamate receptors can result in the death of neu-
rons through a process termed excitotoxicity.
Excitotoxicity has been implicated in several neurodegen-
erative diseases, including Alzheimer disease [9-11],
Huntington disease [12], schizophrenia [13], and bipolar
Published: 28 September 2009
BMC Neuroscience 2009, 10:123 doi:10.1186/1471-2202-10-123
Received: 9 June 2009
Accepted: 28 September 2009
This article is available from: http://www.biomedcentral.com/1471-2202/10/123
© 2009 Kim et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Neuroscience 2009, 10:123 http://www.biomedcentral.com/1471-2202/10/123
Page 2 of 8
(page number not for citation purposes)
disorder [14-16]. Chronic NMDA administration to rats
reduced NMDAR subunits and increased arachidonic acid
cascade markers in rat frontal cortex [6]. Similarly, an
altered NMDAR subunits [17,18] and increased arachi-
donic acid cascade markers have been reported in Alzhe-
imers patients[19,20].
Glutamate was reported to trigger DNA degradation,
apoptotic cell death, and increase the Bcl-2-associated X
protein (Bax) to B-cell lymphoma (Bcl)-2 ratio in cells in
vitro  [21-24]. In addition, AA was reported to induce
apoptosis  in vitro by producing mitochondrial damage
[25], activating caspases-3 and -9, releasing cytochrome C
[26], decreasing expression of brain-derived neurotrophic
factor (BDNF) [27], and reducing neuronal viability [28].
Dietary deprivation of n-3 polyunsaturated fatty acids (n-
3 PUFAs) in rats increased AA signaling while decreasing
BDNF expression in frontal cortex [29,30]. In contrast,
chronic administration of mood stabilizers to rats
decreased brain expression of cPLA2 as well as AA turnover
in brain phospholipids [31]. Mood stabilizers also
increased expression of anti-apoptotic Bcl-2 and BDNF in
the rat frontal cortex [32-34].
We have established an animal model of excessive NMDA
signaling in rats by administering a subconvulsive dose of
NMDA for 21 days. This model demonstrates upregulated
markers of brain AA metabolism, including increased
turnover of AA in brain phospholipids and increased
expression of AA-selective cPLA2 and the cPLA2 gene tran-
scription factor, activator protein (AP)-2 [6,35]. It also
demonstrates increased brain neuroinflammatory mark-
ers, consistent with crosstalk between NMDAR-mediated
excitotoxicity and neuroinflammation [4].
In our present study, we wished to see if chronic NMDA
administration to rats, as a model of excitotoxicity, also
would alter the balance of pro- and anti-apoptotic factors
in brain and lead to neuronal death. To the extent that this
model represents clinical excitotoxicity, it might be used
for drug development and for understanding interactions
among different brain processes that lead to cell death. We
studied the frontal cortex because we had studied this
region previously in this model [4,6].
Methods
Animals
The study was conducted following the National Institutes
of Health Guidelines for the Care and Use of Laboratory
Animals (Publication no. 80-23) and was approved by the
Animal Care and Use Committee of the "Eunice Kennedy
Shriver" National Institute of Child Health and Human
Development. Male CDF-344 rats weighing 200-215 g
(Charles River Laboratories; Wilmington, MA, USA) were
randomly assigned to a control group (n = 10) that
received vehicle (0.9% saline i.p.) once daily for 21 days,
or to an NMDA group (n = 10) that received 25 mg/kg i.p.
NMDA (Sigma Chemical Co., St Louis, MO, USA) once
daily for 21 days. This dose does not produce convulsions
but can cause paroxysmal EEG activity [36] and an
increase in brain AA metabolism in rats [37]. Three hours
after the last saline or NMDA injection, rats were anesthe-
tized with CO2 and then decapitated. The brain was rap-
idly excised and the frontal cortex dissected, frozen in 2-
methylbutane at -50°C, and stored at -80°C until use.
Preparation of Cytosolic Fractions
Cytosolic fractions were prepared from frontal cortex as
previously described [6]. Tissue from control or chronic
NMDA rats was homogenized with a Polytron homoge-
nizer in a buffer consisting of 20 mM Tris-HCl (pH 7.4), 2
mM EGTA, 5 mM EDTA, 1.5 mM pepstatin, 2 mM leupep-
tin, 0.5 mM phenylmethylsulfonyl fluoride, 0.2 U/ml
aprotinin, and 2 mM dithiothreitol. The suspension was
centrifuged at 100,000 × g for 60 min at 4°C. The result-
ing supernatant was the cytosolic fraction. Protein con-
centrations of cytosolic fractions were determined by
using a protein reagent (Bio-Rad, Hercules, CA).
The frontal cortex nuclear fraction was prepared from the
control and NMDA administered rats as previously
described [6].
Western Blot Analysis
Proteins from cytosolic extracts (65 μg) were separated on
10-20% SDS-polyacrylamide gels (PAGE) (Bio-Rad), and
then were electrophoretically transferred to a nitrocellu-
lose membrane (Bio-Rad). Cytosolic blots were incubated
with primary antibodies for BDNF, Bcl-2, Bcl-2-associated
X protein (Bax), Bcl-2-associated death promoter (Bad),
and 14-3-3z (1: 1000) (Santa Cruz Biotech, Santa Cruz,
CA). The blots then were incubated with appropriate
HRP-conjugated secondary antibodies (Bio-Rad) and
were visualized using a chemiluminescence reaction
(Amersham, Piscataway, NJ) on X-ray film (XAR-5,
Kodak, Rochester, NY). Optical densities of immunoblot
bands were measured using Alpha Innotech Software
(Alpha Innotech, San Leandro, CA) and were normalized
to  β-actin (Sigma) to correct for unequal loading. All
experiments were carried out twice with up to 6 independ-
ent samples.
BDNF and phospho-CREB Protein Levels
BDNF and phospho-cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) levels
were measured in brain cytosolic and nuclear extracts
using an ELISA kit according to the manufacturer's
instructions (Chemicon International, Temecula, CA).
BDNF levels are expressed in pmol/mg protein and phos-
pho-CREB levels were expressed as percent of control.BMC Neuroscience 2009, 10:123 http://www.biomedcentral.com/1471-2202/10/123
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Total RNA Isolation and RT-PCR
Total RNA was isolated from frontal cortex of control and
chronic NMDA-administered rats using an RNeasy lipid
tissue mini kit (Qiagen, Valencia, CA, USA). Expression of
BDNF, Bcl-2, Bax, and Bad was determined using specific
primers and probes purchased from TaqManR gene expres-
sion assays (Applied Biosystems). Data were expressed as
the level of the target gene mRNA in brain from NMDA-
administered animals normalized to the level of the
endogenous control mRNA (β-globulin), and relative to
values in brains from control saline-injected rats (calibra-
tor) [38]. All experiments were carried out in duplicate
with six independent samples per group.
FJB staining
Brains from control and NMDA administered rats (frontal
cortex) were sectioned coronally (25 μm) on a cryostat
(Bright Instrument Company, Ltd., Huntingdon, Eng-
land) and then mounted on gelatin-coated glass specimen
slides. Staining with FJB (Histo-Chem, Jefferson, AR) was
performed as described [39]. Briefly, the tissue slides were
dehydrated in 70% ethanol and then hydrated with dis-
tilled water. After hydration, they were immersed in FJB
stain for 20 min at room temperature, washed with dis-
tilled water and dried at 50°C for 10 min. The slides were
mounted with the cover slip with DPX and examined
under a fluorescence microscope.
Statistical Analysis
Data are expressed as means ± SEM. Statistical significance
was calculated using two-tailed, unpaired t-test, with sig-
nificance set at p < 0.05.
Results
Decreased levels of anti-apoptotic factors
Chronic NMDA administration for 21 days, compared
with chronic saline, significantly decreased protein levels
of BDNF (75%; p < 0.001) (Figure 1A), Bcl-2 (33%; p <
Protein levels of BDNF (A) and Bcl-2 (B) in frontal cortex of control rats (n = 10) and chronic NMDA-treated rats (n = 10),  measured using ELISA and immunoblot as described in the method section Figure 1
Protein levels of BDNF (A) and Bcl-2 (B) in frontal cortex of control rats (n = 10) and chronic NMDA-treated 
rats (n = 10), measured using ELISA and immunoblot as described in the method section. Optical densities of 
immunoblot bands were normalized to b-actin to correct for unequal loading. Values are expressed as percent of control. 
Phosphorylated CREB (C) was measured in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats (n = 8) by 
ELISA, as described in manufacturer's instructions. mRNA levels of BDNF (C) and Bcl-2 (D) in frontal cortex of control rats (n 
= 6) and of chronic NMDA-treated rats (n = 6), measured using RT-PCR. Data are expressed as mRNA level in frontal cortex 
of chronic NMDA administered rats, normalized to the endogenous level of β-globulin mRNA, and relative to the control (cal-
ibrator), using the ΔΔCT method (means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001).BMC Neuroscience 2009, 10:123 http://www.biomedcentral.com/1471-2202/10/123
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0.05) (Figure 1B), and phospho-CREB (39%; p < 0.001)
(Figure 1C) in rat frontal cortex. The decreases in these
protein levels were associated with decreases in their
mRNA levels. Thus, chronic NMDA significantly
decreased mRNA levels of BDNF (0.6 fold; p < 0.01) (Fig-
ure 1D) and of Bcl-2 (0.6 fold; p < 0.01) (Figure 1E).
Increased levels of pro-apoptotic factors
In contrast to the reductions in anti-apoptotic factors,
chronic NMDA increased protein levels of pro-apoptotic
Bad (71%; p < 0.05) (Figure 2A) and Bax (30%; p < 0.01)
(Figure 2B). mRNA levels also were increased for both Bad
(1.4 fold; p < 0.05) (Figure 2C) and Bax (0.23 fold; p <
0.05) (Figure 2D) by chronic NMDA. Chronic NMDA
administration increased the protein level of 14-3-
3ζ(50%; p < 0.05) (Figure 3A).
Evidence of cell death
Chronic NMDA administration increased FJB staining, a
marker of neuronal loss, in rat frontal cortex (Figure 3B).
Discussion
Chronic daily administration of a non-convulsive dose of
NMDA to adult male rats significantly decreased frontal
cortex protein and mRNA levels of the anti-apoptotic fac-
tors BDNF and Bcl-2, and of their transcription factor,
phospho-CREB. In contrast, chronic NMDA significantly
increased frontal cortex protein and mRNA levels of Bad
Protein levels of Bad (A) and Bax (B) in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats (n = 8), meas- ured using immunoblot Figure 2
Protein levels of Bad (A) and Bax (B) in frontal cortex of control rats (n = 8) and of chronic NMDA-treated rats 
(n = 8), measured using immunoblot. Optical densities of immunoblot bands were normalized to b-actin to correct for 
unequal loading. Values are expressed as percent of control. Data are expressed as means ± SEM, *p < 0.05, **p < 0.01. mRNA 
levels of Bad (C) and Bax (D) in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured 
using RT-PCR. Data are expressed as mRNA level in frontal cortex of chronic NMDA administered rats, normalized to the 
endogenous level of β-globulin mRNA, and relative to the control (calibrator), using the ΔΔCT method (means ± SEM, *p < 
0.05, **p < 0.01).BMC Neuroscience 2009, 10:123 http://www.biomedcentral.com/1471-2202/10/123
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and Bax and of the protein level of 14-3-3ζ, pro-apoptotic
factors, as well as Fluoro Jade-B staining, a marker of neu-
ronal death, in rat frontal cortex. These data can be added
to evidence that chronic NMDA under the same adminis-
tration paradigm increased frontal cortex expression of
inflammatory markers (protein and mRNA levels of inter-
leukin-1 beta, tumor necrosis factor alpha, glial fibrillary
acidic protein and inducible nitric oxide synthase) [4],
decreased frontal cortex NMDAR (NR)-1 and NR-3A sub-
units, and increased activity, phosphorylation, protein,
and mRNA levels of cPLA2 but did not change activity or
protein levels of secretory sPLA2 or calcium-independent
iPLA2 [6]. Chronic NMDA also increased the DNA-bind-
ing activity of AP-2 and its protein levels of AP-2 alpha
and beta subunits [6], which are recognized on the pro-
moter region of cPLA2 gene [40] as well as turnover and
other kinetic markers of AA metabolism in frontal cortex
of rat brain [35]. These changes did not follow administra-
tion of a single 25 mg/kg i.p. dose of NMDA and thus were
a consequence of long term activation of NMDARs [6].
Together, they provide a profile of an experimental and
probably evolving animal model of excitotoxicity, which
might be exploited for future drug development and for
understanding interactions of processes of excitotoxicity.
There is evidence that excitotoxicity plays a role in a
number of neuropsychiatric and neurodegenerative disor-
ders, including Alzheimer disease [9-11], Huntington's
disease [12], schizophrenia [13], and bipolar disorder
[14,16,41].
The effects of chronic NMDA in rats suggest alterations of
multiple signaling cascades such as calpain [2], cal-
cineurin [3] and iNOS expression [4] but it may be prema-
ture to ascribe a change in one to a change in another.
Nevertheless, increased AA metabolism caused by chronic
NMDA may be involved in altering the balance between
pro- and anti-apoptotic factors, leading in turn to the
observed neuronal loss. Increased AA exposure decreased
A Protein levels of 14-3-3-ζ in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), measured using  immunoblotting Figure 3
A Protein levels of 14-3-3-ζ in frontal cortex of control rats (n = 6) and of chronic NMDA-treated rats (n = 6), 
measured using immunoblotting. Optical densities of immunoblot bands were normalized to b-actin to correct for une-
qual loading. Values are expressed as percent of control. Data are expressed as means ± SEM, *p < 0.05. B. Representative FJB 
stained frontal cortex slices from control and chronic NMDA administered rats. Magnification is at 40 × objective. FJB positive 
neurons were only observed in the brains of chronic NMDA administered rats.BMC Neuroscience 2009, 10:123 http://www.biomedcentral.com/1471-2202/10/123
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BDNF protein in spinal cord neurons in vitro [27],
induced mitochondrial damage [25], activated caspases-3
and -9, released cytochrome C from mitochondria [26]
and decreased neuronal viability [28].
Expression of BDNF and Bcl-2 is regulated mainly by
CREB [42]. BDNF and Bcl-2 play important roles in cell
survival and plasticity, and in growth and differentiation
of new neurons and synapses [43]. Increased AA signaling
may interfere with transcription of neuronal survival fac-
tors [27,44-47]. Downregulation of BDNF and Bcl-2
could occur through a decrease in their transcription fac-
tor phospho-CREB [48], as was found in this study. BDNF
also may regulate Bcl-2 levels through activation of the
MAP kinase cascade and the downstream phosphoryla-
tion of CREB protein [49].
Bcl-2 can be repressed by the AP-2 transcription factor
[50], resulting in apoptosis. Chronic NMDA in rats
increased the DNA-binding activity of AP-2 and protein
levels of its alpha and beta subunits [51]. AP-2 also is a
transcription factor of the cPLA2 gene, and its overexpres-
sion may lead to upregulated cPLA2 activity and of AA sig-
naling upon chronic NMDA administration [51]. Thus,
increased AP-2 binding activity or decreased BDNF caused
by chronic NMDA may have led to the decreased Bcl-2
expression in the present study.
Consistent with the notion that increased AA signaling
reduces BDNF expression, rats deprived of dietary essen-
tial n-3 PUFAs for 15 weeks demonstrated increased brain
AA signaling and reduced mRNA and protein levels of
phospho-CREB and BDNF [29,30]. In relation to this,
chronic NMDA administration also increased brain cPLA2
activity, phosphorylation, protein, and mRNA levels, as
well as AA turnover in brain phospholipids [6,35].
14-3-3ζ proteins bind the pro-apoptotic protein Bad [52].
Disassociation of 14-3-3ζ from Bad causes dephosphor-
ylation of Bad by protein phosphatase 2A [53], allowing
Bad to move from the cytoplasm to mitochondria, where
it can displace Bax from Bcl-xL [54] and promote apopto-
sis. There also may be a more direct mechanism by which
AA induces polymerization of 14-3-3ζ and dissociation
from Bad [55]. The combination of increased expression
of 14-3-3ζ and increased AA signaling [6] caused by
chronic NMDA may have contributed to the neuronal
loss, which is suggested by the increased FJB staining.
Studies also have reported increased protein levels of 14-
3-3ζ associated with neurodegenerative disease [56-58].
Increased 14-3-3ζ protein levels caused by chronic NMDA
may be a secondary response to the observed increased
Bad expression or be due to the increased AA signalling.
Further studies are needed to understand the direct role of
14-3-3ζ in NMDA mediated apoptosis.
Conclusion
Chronic NMDA excitotoxicity may be involved in the
apoptosis in neurodegenerative diseases, while targeting
the excitotoxicity with drugs may be a useful therapeutic
approach in these neurodegenerative diseases by way of
reducing apoptosis in brain.
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